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Androgen deprivation therapy for prostate cancer causes bone loss. Although we reported 
previously that risedronate significantly recovers bone mineral density for up to 12 months, there 
have been no reports with longer follow-up periods to date. The present study extended our earlier 
series extending the follow-up period to 24 months. Eligible patients had histologically confirmed 
prostate cancer without lumbar spine metastasis and underwent androgen deprivation therapy. 
Lumbar spine bone mineral density, urinary deoxypyridinoline, and serum bone alkaline 
phosphatase were measured at 6, 12, and 24 months. Among the total of 96 patients, we analyzed 
26 and 18 patients in risedronate administration and control groups, respectively. Bone mineral 
density relative to the young adult mean ratio, urinary deoxypyridinoline, and serum bone alkaline 
phosphatase of the risedronate administration group recovered significantly after 24 months 
compared with the control group (P<0.0001, P=0.0001, and P<0.0001, respectively). Transient 
blurred vision, malaise, and vertigo were observed in 1 patient each among the 46 patients treated 
with risedronate within 28 days after first administration. Oral administration of risedronate is safe 
and effective for recovery of androgen deprivation therapy-induced bone loss in prostate cancer 
patients even at 24 months after commencement of treatment. 
 




 Prostate cancer (PCa) is the most frequent malignancy in men. In Europe, about 382,000 men 
(11.9% of all cancers) were diagnosed with prostate cancer in 2008 [1]. In the USA, about 192,280 
men (25.1% of male cancers) were diagnosed with prostate cancer in 2009, and this disease is the 
second most frequent cause of cancer-related death in men [2]. Androgen deprivation therapy 
(ADT) is usually performed in patients with locally advanced prostate cancer or metastasis. 
Although ADT is not supported by high level evidence for localized disease, not only in Japan but 
also in the USA, the frequency of ADT being chosen to treat localized disease is also increasing in 
clinical practice, especially in elderly patients with multiple comorbidities [3, 4]. Over 600,000 men 
with PCa in the USA are treated annually with ADT [5]. Osteoporosis is a serious complication of 
long-term ADT [6]. Bisphosphonates are agents that inhibit proliferation and differentiation of 
osteoclasts and repress bone resorption by osteoclasts, and have already been used for treatment of 
primary osteoporosis. Risedronate is a third-generation oral bisphosphonate. We reported 
previously that bone mineral density (BMD) of the risedronate administration group recovered 
significantly after 12 months compared with the control group [7]. Although long-term and 
continuous ADT was shown to be highly efficacious in localized PCa [8], there have been no 
reports regarding treatment with risedronate over periods longer than 12 months. The present study 
extended our earlier series to prolong follow-up, and allowed evaluation of whether risedronate 
recovered decreases in BMD of the lumbar spine caused by ADT through 24 months. 
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All studies were performed after receiving approval from the Institutional Review Board of 
the Graduate School of Medical Science, Kanazawa University. This prospective observational 
study was performed with the same patient selection criteria as used previously [7]. However, some 
patients did not complete 24 months of the study, and 44 of 96 patients initially enrolled were 
available for analysis. Patients diagnosed with histologically proven PCa and treated with ADT 
(combination of luteinizing hormone-releasing hormone agonist and antiandrogens or 
monotherapy of luteinizing hormone-releasing hormone agonist) or newly diagnosed with PCa and 
scheduled for treatment with ADT were enrolled in this study. The patients with lumbar bone 
metastasis diagnosed with bone scintigraphy or who were previously treated with drugs that 
interfere with bone metabolism (bisphosphonates, calcitonin, vitamin D) were excluded from the 
study. After obtaining written informed consent from the patients, BMD of the lumbar spine was 
measured by dual-energy X-ray absorptiometry (DXA). We evaluated BMD relative to the young 
adult mean (YAM) because osteoporosis is diagnosed when BMD falls below 70% of YAM in 
Japan [9], and then divided patients into 2 groups. If the BMD/YAM ratio was less than 90%, we 
recommended patients take risedronate with ADT (risedronate administration group); if not, we 
recommended they be enrolled only for ADT (control group). However, we also took the patient’s 
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wishes into consideration regarding enrolling in the study. A dose of 2.5 mg/day of risedronate was 
administered orally for 24 months in the risedronate administration group. 
 
Measurement of bone mineral density and bone-related values 
 
 BMD was measured in all patients by DXA at baseline and after 6, 12, and 24 months at the 
lumbar spine (L2 to L4), and BMD/YAM ratio was calculated as a percentage. Serum testosterone 
(T, normal range 3.3–7.4 ng/mL) and prostate-specific antigen (PSA, normal range 0–4.0 ng/mL) 
were measured at baseline. Urinary deoxypyridinoline (uDPD, normal range 2.1–5.4 nmol/mmol 
urinary creatinine) and serum bone alkaline phosphatase (BAP, normal range 7.9–29.0 U/L) were 
measured at baseline and after 6, 12, and 24 months. Both urine and serum samples for 




Statistical analyses were performed using commercially available software (Prism). Endpoint 
values after 6, 12, and 24 months of treatment were compared with baseline values on enrollment 
by paired t test. Comparison of changes between groups after 6, 12, and 24 months of treatment 
was performed by unpaired two-sided t test at the 0.05 significance level. All data are presented as 






Of the total of 96 patients (risedronate administration group, n=46; control group, n=50) 
initially enrolled in this study, 52 patients (risedronate administration group, n=20; control group, 
n=32 patients) were excluded from the analyses for several reasons as follows. 
Risedronate administration group: lost to follow-up, n=5; changed hospital, n=1; withdrawal 
of ADT, n=4; commencement of zoledronate, n=1; commencement of alendronate, n=1; exodontia, 
n=1; follow-up did not reach 24 months, n=4; adverse events, n=3. 
Control group: lost to follow-up, n=4; changed hospital, n=3; withdrawal of ADT, n=11; 
commencement of risedronate, n=3; commencement of alendronate, n=1; commencement of 
minodronate, n=1; commencement of vitamin D, n=1; external beam radiation therapy, n=1; 
follow-up did not reach 24 months, n=7. 
In 44 patients, the mean age was 73.6 years (range, 58–88) and median ADT duration was 
15.0 months (range, 0–57). Twenty-six patients were assigned to the risedronate administration 
group, and 18 patients were assigned to the control group. At baseline, age, T, PSA, uDPD, and 
BAP were not different between the risedronate administration group and the control group. 
However, T of 3 patients in the control group was not measured. On the other hand, BMD and 
BMD/YAM ratio of the risedronate administration group were significantly lower than those of the 
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control group (mean BMD/YAM ratio: 83.6% vs. 99.7%, respectively). ADT duration of the 
risedronate administration group was also significantly longer than that of the control group 
(median ADT duration: 18 months vs.10 months) (Table 1). These significant differences were 
expected because patients were divided on the basis of BMD/YAM ratio at enrollment. 
 
Changes in bone mineral density and bone turnover markers 
 
BMD/YAM ratio of the lumbar spine increased significantly from the baseline in patients in 
the risedronate administration group after 12 and 24 months (12 months, +2.55%±3.29%, 
P=0.0005; 24 months, +5.79%±6.37%, P<0.0001) although ADT decreased BMD/YAM ratio in 
the control group after 6, 12, and 24 months (6 months, –1.31%±2.6%, P=0.0478; 12 months, 
–2.56%±3.37%, P=0.0050; 24 months, –4.34%±6.21%, P=0.0087). BMD/YAM ratio of the 
risedronate administration group recovered significantly after 12 and 24 months compared with the 
control group (12 months, P<0.0001; 24 months, P<0.0001) (Table 2 and Fig. 1). The bone 
resorption marker uDPD was significantly decreased after 12 and 24 months from the baseline in 
the risedronate administration group (12 months, –14.5%±25.6%, P=0.0080; 24 months, 
–24.4%±25.5%, P= 0.0001). In addition, uDPD was significantly decreased after 12 and 24 
months in the risedronate administration group compared with the control group (12 months, 
P=0.0217; 24 months, P=0.0001) (Table 2 and Fig. 2). However, uDPD was not measured in 3 
patients at 24 months in the risedronate administration group, and they were excluded from the 
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analysis. The osteogenic marker BAP was significantly decreased after 6, 12, and 24 months from 
the baseline in the risedronate administration group (6 months, –13.5%±20.4%, P=0.0331; 12 
months, –22.6%±23.2%, P<0.0001; 24 months, –32.5%±23.5%, P<0.0001). BAP was 
significantly increased after 12 months from the baseline in the control group (+25.6%±27.5%, 
P=0.0011). In addition, BAP was significantly decreased after 6, 12, and 24 months in the 
risedronate administration group as compared with the control group (6 months, P=0.0260; 12 




Transient blurred vision, malaise, and vertigo (Grade 1 of National Cancer Institute-Common 
Terminology Criteria for Adverse Events version 3.0) were observed in 1 patient each among the 
46 patients treated with risedronate within 28 days after the first administration. The symptoms in 




Continuous ADT decreases BMD and increases the risk of bone fracture [10–12]. 
Bisphosphonates have already been used for treatment of primary osteoporosis and were also 
reported to prevent bone loss caused by ADT [13]. Smith et al. reported that patients undergoing 
ADT who received 60 mg of pamidronate intravenously every 12 weeks exhibited no significant 
changes from baseline BMD at the lumbar spine, total hip, and trochanter, in contrast, placebo 
group had significant decreases from baseline BMD [14]. They also reported that mean BMD in 
the lumbar spine increased by 5.6% in patients undergoing ADT who received 4 mg zoledronate 
intravenously every 3 months for 1 year, and decreased by 2.2% in those given placebo [15]. After 
this report, there have been reported to show zoledronate consistently increase BMD beyond 
baseline levels in several studies [16]. On the other hand, oral bisphosphonates including 
risedronate also have been developed for their convenient administration. Ishizaki et al. reported 
that risedronate prevented bone loss of the femoral neck and can reverse bone loss of the lumbar 
spine in men receiving ADT for PCa [17]. This was the first report confirming the effect of 
risedronate on bone loss in PCa patients treated with ADT. A major limitation of their study was a 
lack of a placebo control group. Moreover, the follow-up period of 6 months may have been too 
short, because long-term and continuous ADT may be needed for PCa [8]. In our previous study, 
the follow-up period was 12 months and the risedronate administration group gained a mean of 
2.6% in BMD/YAM ratio at the lumbar spine, while the control group lost 2.8% (P<0.001). The 
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control group was set but not randomized [7]. Taxel et al. recently reported the results of a 
randomized, double-blind, placebo-controlled trial [18]. In their study, 40 men receiving luteinizing 
hormone-releasing hormone agonist for 6 months for locally advanced PCa were randomized in 
the risedronate administration group and the control group. Although the control group showed a 
decline in BMD at the lumbar spine and the hip, the risedronate administration group had no bone 
loss at the hip and an increase at the lumbar spine (1.7%, P=0.04). In addition, bone turnover 
markers including N-telopeptide, serum C-telopeptide, and procollagen peptide, and 25-OH 
vitamin D and intact parathyroid hormone were increased significantly in the control group but 
remained unchanged in the risedronate administration group. Although their report was very 
important as the first randomized trial of risedronate, the follow-up period was only 6 months and 
dose of weekly 35 mg risedronate was double that in our setting. In the present study, bone mineral 
density of the lumbar spine at 24 months increased by 5.79% in the risedronate administration 
group as compared with a loss of 4.38% in the control group (P<0.0001). A marginally significant 
difference was seen between the 2 groups at 6 months. At 12 months, a significant difference was 
seen between the 2 groups, which was sustained through 24 months. To our knowledge, this is the 
first report to clarify the effect of risedronate for bone loss in PCa patients treated with ADT with a 
24-month follow-up. Although Greenspan et al. reported that PCa patients treated with ADT 
receiving alendronate for 24 months showed a mean 6.7% increase at the lumbar spine, the control 
group also received alendronate for at least 12 months [19]. In addition, their patients received 
calcium and vitamin D. In the present study, significant differences in bone turnover markers, 
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including BAP and uDPD, between the risedronate administration group and the control group 
were also seen at 12 months and sustained through 24 months. The difference in percent change of 
the BMD/YAM ratio between the 2 groups at 24 months in the present study was >10%, and our 
results provide preliminary evidence in support of continuing oral bisphosphonate therapy for 24 
months. 
In general, bisphosphonates are well tolerated [20], and the most common adverse events 
associated with oral bisphosphonates are mild nausea and arthralgia [21, 22]. There have been 
recent reports of osteonecrosis of the jaw occurring in cancer patients treated with intravenous 
bisphosphonates, although it was reported that the prevalence of osteonecrosis of the jaw in patients 
receiving oral bisphosphonate for treatment of osteoporosis was low [23]. Consistent with these 
previously reported studies, minor adverse events were observed in only 3 patients in the 
risedronate administration group in the present study. 
Our study had a number of limitations. The study design did not determine the incidence of 
fracture, although the risk of skeletal fractures is positively correlated with low BMD in healthy 
men and fragility fractures occur as often or more frequently in men with osteopenia as in those 
with osteoporosis [24, 25]. Moreover, short follow-up may have prevented determination of the 
precise statistical significance and incidence of adverse events, and patients were not randomized 
when they were assigned to each group. Small sample size may also result in incorrect statistical 
significance and incidence of adverse events. Actually, only 44 of 96 initially enrolled patients 
could be analyzed. All patients were Japanese, so risedronate may not have the same effects in 
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patients from other ethnic backgrounds, especially with regard to dose. Larger prospective studies 
with longer follow-up period are needed to confirm our findings. 
Finally, our study provided evidence that daily oral administration of risedronate was effective 
in preventing bone loss in PCa patients treated with ADT at 24 months. Currently, higher doses of 
risedronate (17.5 mg–150 mg) are available, and monthly administration has been shown to have 
equivalent efficacy and tolerability to weekly dosing [26, 27]. This may improve compliance in 
aging men who comprise the majority of PCa patients. Our data show that PCa patients treated 
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Legends to figures 
 
Fig. 1 – Mean % changes in BMD/YAM ratio. BMD/YAM ratio of risedronate administration 
group showed significant recovery not only after 12 months but also after 24 months compared 
with the control group. R: risedronate administration, C: control. 
 
Fig. 2 – Mean % changes in uDPD. uDPD was significantly decreased not only after 12 months 
but also after 24 months in the risedronate administration group compared with the control group. 
R: risedronate administration, C: control. 
 
Fig. 3 – Mean % changes in BAP. BAP was significantly decreased not only after 6 and 12 months 
but also after 24 months in the risedronate administration group compared with the control group. 





73.3 (58-88) 73.9 (59-83) 0.7890
0.06 (0.02-0.25) 0.12 (0.02-5.58) 0.0559
0.042 (0.008-0.576) 0.056 (0.008-177.5) 0.1404
18 (2-57) 10 (0-26) 0.0152
0.992 (0.74-1.40) 1.18 (0.97-1.80) 0.0020
83.6 (65-117) 99.7 (84-152) 0.0016
6.87 (4.1-10.0) 6.48 (4.1-12.2) 0.4918
30.3 (16.8-75.2) 28.4 (11.1-48.8) 0.5678
Mean BMD (g/cm2)
Mean BMD/YAM ratio (%)
Mean uDPD (nmol/mmol Creatinine)
Mean Age (year)
Mean BAP (U/L)
Median ADT duration (months)
Median T (ng/mL)
Median PSA (ng/mL)
Table 1. Patient characteristics at baseline
Case
ADT, Androgen-deprivation therapy; T, Testosterone; PSA, Prostate specific antigen; BMD, Bone
mineral density; YAM, Young adult mean; uDPD, Urinary deoxypyridinoline; BAP, Bone alkaline
phosphatase.
Variables Risedronate (range) Control (range) p  value
mean (SD) p valueap  valueb mean (SD) p valueap valueb mean (SD) p valueap  valueb
Risedronate+1.48 (5.44) 0.1869 +2.55 (3.29) 0.0005 +5.79 (6.37)<0.0001
Control -1.31 (2.6) 0.0478 -2.56 (3.37) 0.0050 -4.34 (6.21) 0.0087
Risedronate-9.19 (26.2) 0.0857 -14.5 (25.6) 0.0080 -24.4 (25.5) 0.0001
Control -2.94 (17.4) 0.4826 +7.18 (34.7) 0.3921 +13.2 (30.2) 0.0806
Risedronate-13.5 (20.4) 0.0331 -22.6 (23.2) <0.0001 -32.5 (23.5) <0.0001
Control +5.70 (21.2) 0.2696 +25.6 (27.5) 0.0011 +20.0 (27.4) 0.0703
Table 2. % changes in bone mineral density and bone turnover markers





ADT, Androgen-deprivation therapy; BMD, Bone mineral density; YAM, Young adult mean; uDPD,
Urinary deoxypyridinoline; BAP, Bone alkaline phosphatase;  a Comparison with basal values, b Comparison
between risedronate-administrated group and control group
uDPD 0.3810 0.0217 0.0001
BAP 0.0260 <0.0001 <0.0001
